Is SYRE or RAPP more profitable?

Rapport Therapeutics' return on equity of -24.78% beat Spyre Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Spyre Therapeutics N/A -42.88% -27.76% Rapport Therapeutics N/A -24.78% -23.44%

Does the media refer more to SYRE or RAPP?

In the previous week, Spyre Therapeutics had 5 more articles in the media than Rapport Therapeutics. MarketBeat recorded 10 mentions for Spyre Therapeutics and 5 mentions for Rapport Therapeutics. Rapport Therapeutics' average media sentiment score of 1.21 beat Spyre Therapeutics' score of 0.32 indicating that Rapport Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyre Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Rapport Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to RAPP or KYMR?

In the previous week, Kymera Therapeutics had 12 more articles in the media than Rapport Therapeutics. MarketBeat recorded 17 mentions for Kymera Therapeutics and 5 mentions for Rapport Therapeutics. Rapport Therapeutics' average media sentiment score of 1.21 beat Kymera Therapeutics' score of 0.17 indicating that Rapport Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rapport Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kymera Therapeutics 6 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is PRAX or RAPP more profitable?

Rapport Therapeutics' return on equity of -24.78% beat Praxis Precision Medicines' return on equity. Company Net Margins Return on Equity Return on Assets Praxis Precision Medicines N/A -43.02% -40.22% Rapport Therapeutics N/A -24.78% -23.44%

Does the media refer more to PRAX or RAPP?

In the previous week, Praxis Precision Medicines had 4 more articles in the media than Rapport Therapeutics. MarketBeat recorded 9 mentions for Praxis Precision Medicines and 5 mentions for Rapport Therapeutics. Rapport Therapeutics' average media sentiment score of 1.21 beat Praxis Precision Medicines' score of 0.66 indicating that Rapport Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Praxis Precision Medicines 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Rapport Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, RAPP or PCVX?

Rapport Therapeutics is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rapport Therapeutics N/A N/A -$111.48M -$2.60 N/A Vaxcyte N/A N/A -$766.63M -$6.88 N/A

Is RAPP or PCVX more profitable?

Rapport Therapeutics' return on equity of -24.78% beat Vaxcyte's return on equity. Company Net Margins Return on Equity Return on Assets Rapport Therapeutics N/A -24.78% -23.44% Vaxcyte N/A -32.51% -29.51%

Does the media favor RAPP or PCVX?

In the previous week, Vaxcyte had 9 more articles in the media than Rapport Therapeutics. MarketBeat recorded 14 mentions for Vaxcyte and 5 mentions for Rapport Therapeutics. Rapport Therapeutics' average media sentiment score of 1.21 beat Vaxcyte's score of 0.45 indicating that Rapport Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rapport Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vaxcyte 7 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer PTGX or RAPP?

In the previous week, Protagonist Therapeutics had 1 more articles in the media than Rapport Therapeutics. MarketBeat recorded 6 mentions for Protagonist Therapeutics and 5 mentions for Rapport Therapeutics. Rapport Therapeutics' average media sentiment score of 1.21 beat Protagonist Therapeutics' score of 1.09 indicating that Rapport Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protagonist Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rapport Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Rapport Therapeutics (RAPP) Competitors

$40.02 +1.14 (+2.94%)

Closing price 03:59 PM Eastern

Extended Trading

$40.08 +0.05 (+0.13%)

As of 05:51 PM Eastern

Compare

RAPP vs. SYRE, KYMR, PRAX, PCVX, and PTGX

Should you buy Rapport Therapeutics stock or one of its competitors? MarketBeat compares Rapport Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Rapport Therapeutics include Spyre Therapeutics (SYRE), Kymera Therapeutics (KYMR), Praxis Precision Medicines (PRAX), Vaxcyte (PCVX), and Protagonist Therapeutics (PTGX). These companies are all part of the "pharmaceutical products" industry.

How does Rapport Therapeutics compare to Spyre Therapeutics?

Spyre Therapeutics (NASDAQ:SYRE) and Rapport Therapeutics (NASDAQ:RAPP) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, media sentiment, risk, analyst recommendations, valuation and institutional ownership.

80.4% of Spyre Therapeutics shares are held by institutional investors. 15.7% of Spyre Therapeutics shares are held by company insiders. Comparatively, 12.5% of Rapport Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Spyre Therapeutics had 5 more articles in the media than Rapport Therapeutics. MarketBeat recorded 10 mentions for Spyre Therapeutics and 5 mentions for Rapport Therapeutics. Rapport Therapeutics' average media sentiment score of 1.21 beat Spyre Therapeutics' score of 0.32 indicating that Rapport Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyre Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rapport Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Spyre Therapeutics has a beta of 3.05, indicating that its share price is 205% more volatile than the broader market. Comparatively, Rapport Therapeutics has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market.

Spyre Therapeutics currently has a consensus target price of $95.83, suggesting a potential upside of 11.12%. Rapport Therapeutics has a consensus target price of $57.86, suggesting a potential upside of 44.56%. Given Rapport Therapeutics' higher probable upside, analysts clearly believe Rapport Therapeutics is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Rapport Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91

Rapport Therapeutics has lower revenue, but higher earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Rapport Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	$890K	8,414.70	-$155.20M	-$2.08	N/A
Rapport Therapeutics	N/A	N/A	-$111.48M	-$2.60	N/A

Rapport Therapeutics' return on equity of -24.78% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-42.88%	-27.76%
Rapport Therapeutics	N/A	-24.78%	-23.44%

Summary

Spyre Therapeutics beats Rapport Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Rapport Therapeutics compare to Kymera Therapeutics?

Rapport Therapeutics (NASDAQ:RAPP) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends.

In the previous week, Kymera Therapeutics had 12 more articles in the media than Rapport Therapeutics. MarketBeat recorded 17 mentions for Kymera Therapeutics and 5 mentions for Rapport Therapeutics. Rapport Therapeutics' average media sentiment score of 1.21 beat Kymera Therapeutics' score of 0.17 indicating that Rapport Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rapport Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kymera Therapeutics	6 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Rapport Therapeutics currently has a consensus price target of $57.86, suggesting a potential upside of 44.56%. Kymera Therapeutics has a consensus price target of $117.14, suggesting a potential upside of 17.29%. Given Rapport Therapeutics' higher possible upside, research analysts clearly believe Rapport Therapeutics is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rapport Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91
Kymera Therapeutics	1 Sell rating(s)	0 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.96

Rapport Therapeutics has higher earnings, but lower revenue than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Rapport Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rapport Therapeutics	N/A	N/A	-$111.48M	-$2.60	N/A
Kymera Therapeutics	$39.21M	209.52	-$311.35M	-$3.57	N/A

Rapport Therapeutics has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -611.94%. Kymera Therapeutics' return on equity of -24.71% beat Rapport Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rapport Therapeutics	N/A	-24.78%	-23.44%
Kymera Therapeutics	-611.94%	-24.71%	-22.05%

Rapport Therapeutics has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market. Comparatively, Kymera Therapeutics has a beta of 2.02, indicating that its stock price is 102% more volatile than the broader market.

Summary

Kymera Therapeutics beats Rapport Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Rapport Therapeutics compare to Praxis Precision Medicines?

Praxis Precision Medicines (NASDAQ:PRAX) and Rapport Therapeutics (NASDAQ:RAPP) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, profitability, analyst recommendations, earnings and dividends.

Praxis Precision Medicines has a beta of 2.71, suggesting that its share price is 171% more volatile than the broader market. Comparatively, Rapport Therapeutics has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market.

Praxis Precision Medicines presently has a consensus price target of $566.21, suggesting a potential upside of 83.28%. Rapport Therapeutics has a consensus price target of $57.86, suggesting a potential upside of 44.56%. Given Praxis Precision Medicines' stronger consensus rating and higher possible upside, equities analysts plainly believe Praxis Precision Medicines is more favorable than Rapport Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Praxis Precision Medicines	2 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	4 Strong Buy rating(s)	2.95
Rapport Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91

Rapport Therapeutics' return on equity of -24.78% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Praxis Precision Medicines	N/A	-43.02%	-40.22%
Rapport Therapeutics	N/A	-24.78%	-23.44%

67.8% of Praxis Precision Medicines shares are owned by institutional investors. 3.0% of Praxis Precision Medicines shares are owned by company insiders. Comparatively, 12.5% of Rapport Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Praxis Precision Medicines had 4 more articles in the media than Rapport Therapeutics. MarketBeat recorded 9 mentions for Praxis Precision Medicines and 5 mentions for Rapport Therapeutics. Rapport Therapeutics' average media sentiment score of 1.21 beat Praxis Precision Medicines' score of 0.66 indicating that Rapport Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Praxis Precision Medicines	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Rapport Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rapport Therapeutics has lower revenue, but higher earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Rapport Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Praxis Precision Medicines	$8.55M	1,007.40	-$303.27M	-$13.37	N/A
Rapport Therapeutics	N/A	N/A	-$111.48M	-$2.60	N/A

Summary

Praxis Precision Medicines beats Rapport Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Rapport Therapeutics compare to Vaxcyte?

Rapport Therapeutics (NASDAQ:RAPP) and Vaxcyte (NASDAQ:PCVX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

Rapport Therapeutics' return on equity of -24.78% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rapport Therapeutics	N/A	-24.78%	-23.44%
Vaxcyte	N/A	-32.51%	-29.51%

In the previous week, Vaxcyte had 9 more articles in the media than Rapport Therapeutics. MarketBeat recorded 14 mentions for Vaxcyte and 5 mentions for Rapport Therapeutics. Rapport Therapeutics' average media sentiment score of 1.21 beat Vaxcyte's score of 0.45 indicating that Rapport Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rapport Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vaxcyte	7 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Rapport Therapeutics is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rapport Therapeutics	N/A	N/A	-$111.48M	-$2.60	N/A
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A

96.8% of Vaxcyte shares are owned by institutional investors. 12.5% of Rapport Therapeutics shares are owned by company insiders. Comparatively, 3.3% of Vaxcyte shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Rapport Therapeutics has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market. Comparatively, Vaxcyte has a beta of 1.24, meaning that its stock price is 24% more volatile than the broader market.

Rapport Therapeutics currently has a consensus price target of $57.86, suggesting a potential upside of 44.56%. Vaxcyte has a consensus price target of $86.00, suggesting a potential upside of 59.64%. Given Vaxcyte's higher probable upside, analysts plainly believe Vaxcyte is more favorable than Rapport Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rapport Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Summary

Rapport Therapeutics beats Vaxcyte on 9 of the 14 factors compared between the two stocks.

How does Rapport Therapeutics compare to Protagonist Therapeutics?

Protagonist Therapeutics (NASDAQ:PTGX) and Rapport Therapeutics (NASDAQ:RAPP) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, profitability, analyst recommendations, valuation, earnings and risk.

Rapport Therapeutics has lower revenue, but higher earnings than Protagonist Therapeutics. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Rapport Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$46.02M	170.70	-$130.15M	-$1.81	N/A
Rapport Therapeutics	N/A	N/A	-$111.48M	-$2.60	N/A

98.6% of Protagonist Therapeutics shares are owned by institutional investors. 5.2% of Protagonist Therapeutics shares are owned by company insiders. Comparatively, 12.5% of Rapport Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Rapport Therapeutics has a net margin of 0.00% compared to Protagonist Therapeutics' net margin of -154.88%. Protagonist Therapeutics' return on equity of -17.76% beat Rapport Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%
Rapport Therapeutics	N/A	-24.78%	-23.44%

Protagonist Therapeutics presently has a consensus price target of $115.21, suggesting a potential downside of 5.68%. Rapport Therapeutics has a consensus price target of $57.86, suggesting a potential upside of 44.56%. Given Rapport Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Rapport Therapeutics is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
Rapport Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91

In the previous week, Protagonist Therapeutics had 1 more articles in the media than Rapport Therapeutics. MarketBeat recorded 6 mentions for Protagonist Therapeutics and 5 mentions for Rapport Therapeutics. Rapport Therapeutics' average media sentiment score of 1.21 beat Protagonist Therapeutics' score of 1.09 indicating that Rapport Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protagonist Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rapport Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Protagonist Therapeutics has a beta of 1.85, suggesting that its stock price is 85% more volatile than the broader market. Comparatively, Rapport Therapeutics has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market.

Summary

Protagonist Therapeutics beats Rapport Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Rapport Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RAPP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RAPP vs. The Competition

Export

Metric	Rapport Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.86B	$3.49B	$6.74B	$12.32B
Dividend Yield	N/A	2.28%	2.68%	5.88%
P/E Ratio	-15.39	20.50	25.39	23.96
Price / Sales	N/A	328.65	530.17	107.90
Price / Cash	N/A	130.96	45.29	53.76
Price / Book	3.94	8.26	10.76	6.41
Net Income	-$111.48M	$23.91M	$3.56B	$337.14M
7 Day Performance	8.55%	3.05%	1.37%	-0.48%
1 Month Performance	6.11%	2.40%	0.81%	0.49%
1 Year Performance	223.30%	56.35%	30.53%	28.16%

Rapport Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RAPP Rapport Therapeutics	3.1913 of 5 stars	$40.02 +2.9%	$57.86 +44.6%	+257.4%	$1.86B	N/A	N/A	N/A	Positive News Analyst Forecast High Trading Volume
SYRE Spyre Therapeutics	1.6831 of 5 stars	$83.41 -0.2%	$94.17 +12.9%	+561.1%	$7.24B	$890K	N/A	73	Analyst Forecast Insider Trade Gap Down
KYMR Kymera Therapeutics	2.0021 of 5 stars	$87.44 +2.2%	$117.14 +34.0%	+112.2%	$7.19B	$39.21M	N/A	170	News Coverage Insider Trade
PRAX Praxis Precision Medicines	2.9762 of 5 stars	$257.25 -2.8%	$572.72 +122.6%	+633.5%	$7.17B	$8.55M	N/A	110
PCVX Vaxcyte	2.6703 of 5 stars	$49.31 -0.5%	$86.00 +74.4%	+56.3%	$7.12B	N/A	N/A	160

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RAPP) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rapport Therapeutics (RAPP) Competitors

RAPP vs. SYRE, KYMR, PRAX, PCVX, and PTGX

How does Rapport Therapeutics compare to Spyre Therapeutics?

Summary

How does Rapport Therapeutics compare to Kymera Therapeutics?

Summary

How does Rapport Therapeutics compare to Praxis Precision Medicines?

Summary

How does Rapport Therapeutics compare to Vaxcyte?

Summary

How does Rapport Therapeutics compare to Protagonist Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RAPP vs. The Competition

Rapport Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rapport Therapeutics (RAPP) Competitors

RAPP vs. SYRE, KYMR, PRAX, PCVX, and PTGX

How does Rapport Therapeutics compare to Spyre Therapeutics?

Do insiders & institutionals have more ownership in SYRE or RAPP?

Does the media refer more to SYRE or RAPP?

Which has more volatility & risk, SYRE or RAPP?

Do analysts rate SYRE or RAPP?

Which has preferable earnings & valuation, SYRE or RAPP?

Is SYRE or RAPP more profitable?

Summary

How does Rapport Therapeutics compare to Kymera Therapeutics?

Does the media refer more to RAPP or KYMR?

Do analysts rate RAPP or KYMR?

Which has higher earnings and valuation, RAPP or KYMR?

Is RAPP or KYMR more profitable?

Which has more volatility and risk, RAPP or KYMR?

Summary

How does Rapport Therapeutics compare to Praxis Precision Medicines?

Which has more volatility & risk, PRAX or RAPP?

Do analysts prefer PRAX or RAPP?

Is PRAX or RAPP more profitable?

Do insiders & institutionals have more ownership in PRAX or RAPP?

Does the media refer more to PRAX or RAPP?

Which has stronger earnings & valuation, PRAX or RAPP?

Summary

How does Rapport Therapeutics compare to Vaxcyte?

Is RAPP or PCVX more profitable?

Does the media favor RAPP or PCVX?

Which has preferable earnings and valuation, RAPP or PCVX?

Do institutionals and insiders hold more shares of RAPP or PCVX?

Which has more risk and volatility, RAPP or PCVX?

Do analysts prefer RAPP or PCVX?

Summary

How does Rapport Therapeutics compare to Protagonist Therapeutics?

Which has higher valuation and earnings, PTGX or RAPP?

Do institutionals & insiders have more ownership in PTGX or RAPP?

Is PTGX or RAPP more profitable?

Do analysts prefer PTGX or RAPP?

Does the media prefer PTGX or RAPP?

Which has more risk & volatility, PTGX or RAPP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RAPP vs. The Competition

Rapport Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools